{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:01:30Z","timestamp":1762642890565,"version":"build-2065373602"},"reference-count":99,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Liga Portuguesa Contra o Cancro-Centro Regional do Norte (Portuguese League Against Cancer)","award":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"],"award-info":[{"award-number":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"]}]},{"name":"IPO Porto","award":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"],"award-info":[{"award-number":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"],"award-info":[{"award-number":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"]}]},{"name":"FCT\/MCTES","award":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"],"award-info":[{"award-number":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"]}]},{"name":"FCT","award":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"],"award-info":[{"award-number":["CI-IPOP-22-2015","CI-IPOP-BPD2018-UID-DTP-00776-POCI-01-0145-FEDER-006868-GOMPV","UID\/DTP\/00776\/POCI-01-0145-FEDER-006868","2020.08969.BD"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer (PCa) is one of the most common malignancies among men worldwide. Inevitably, all advanced PCa patients develop metastatic castration-resistant prostate cancer (mCRPC), an aggressive phase of the disease. Treating mCRPC is challenging, and prognostic tools are needed for disease management. MicroRNA (miRNA) deregulation has been reported in PCa, constituting potential non-invasive prognostic biomarkers. As such, this study aimed to evaluate the prognostic potential of nine miRNAs in the liquid biopsies (plasma) of mCRPC patients treated with second-generation androgen receptor axis-targeted (ARAT) agents, abiraterone acetate (AbA) and enzalutamide (ENZ). Low expression levels of miR-16-5p and miR-145-5p in mCRPC patients treated with AbA were significantly associated with lower progression-free survival (PFS). The two miRNAs were the only predictors of the risk of disease progression in AbA-stratified analyses. Low miR-20a-5p levels in mCRPC patients with Gleason scores of &lt;8 were associated with worse overall survival (OS). The transcript seems to predict the risk of death regardless of the ARAT agent. According to the in silico analyses, miR-16-5p, miR-145-5p, and miR-20a-5p seem to be implicated in several processes, namely, cell cycle, proliferation, migration, survival, metabolism, and angiogenesis, suggesting an epigenetic mechanism related to treatment outcome. These miRNAs may represent attractive prognostic tools to be used in mCRPC management, as well as a step further in the identification of new potential therapeutic targets, to use in combination with ARAT for an improved treatment outcome. Despite the promising results, real-world validation is necessary.<\/jats:p>","DOI":"10.3390\/ijms24109101","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T03:20:06Z","timestamp":1684812006000},"page":"9101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Plasmatic MicroRNAs and Treatment Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer: A Hospital-Based Cohort Study and In Silico Analysis"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-4669","authenticated-orcid":false,"given":"Jani","family":"Silva","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"AquaValor\u2014Centro de Valoriza\u00e7\u00e3o e Transfer\u00eancia de Tecnologia da \u00c1gua, Rua Dr. J\u00falio Martins, n\u00ba1, 5400-342 Chaves, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-7757","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Abel Salazar Institute for the Biomedical Sciences (ICBAS), Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Ana","family":"Afonso","sequence":"additional","affiliation":[{"name":"Department of Oncology, Portuguese Institute of Oncology, Rua Dr. Ant\u00f3nio Bernardino Almeida, 4200-072 Porto, Portugal"}]},{"given":"Juliana","family":"Garcia","sequence":"additional","affiliation":[{"name":"AquaValor\u2014Centro de Valoriza\u00e7\u00e3o e Transfer\u00eancia de Tecnologia da \u00c1gua, Rua Dr. J\u00falio Martins, n\u00ba1, 5400-342 Chaves, Portugal"},{"name":"Centre for the Research and Technology of Agro-Environment and Biological Sciences (CITAB)\/Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), University of Tr\u00e1s-os-Montes e Alto Douro, 5001-801 Vila Real, Portugal"}]},{"given":"F\u00e1tima","family":"Cerqueira","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o, Inova\u00e7\u00e3o e Desenvolvimento Fernando Pessoa (FP-I3ID), Biomedical and Health Sciences (FP-BHS), Universidade Fernando Pessoa, Pra\u00e7a 9 de Abril, 349, 4249-004 Porto, Portugal"},{"name":"Faculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Department, Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Abel Salazar Institute for the Biomedical Sciences (ICBAS), Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o, Inova\u00e7\u00e3o e Desenvolvimento Fernando Pessoa (FP-I3ID), Biomedical and Health Sciences (FP-BHS), Universidade Fernando Pessoa, Pra\u00e7a 9 de Abril, 349, 4249-004 Porto, Portugal"},{"name":"Faculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barsouk, A., Padala, S.A., Vakiti, A., Mohammed, A., Saginala, K., Thandra, K.C., Rawla, P., and Barsouk, A. (2020). Epidemiology, Staging and Management of Prostate Cancer. Med. Sci., 8.","DOI":"10.3390\/medsci8030028"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.04.010","article-title":"Androgens in prostate cancer: A tale that never ends","volume":"516","author":"Hou","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","article-title":"Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment","volume":"1096","author":"Mansinho","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chung, M.S., and Lee, S.H. (2018). Side Effects and Management of ADT for Prostate Cancer. Manag. Adv. Prostate Cancer, 149\u2013156.","DOI":"10.1007\/978-981-10-6943-7_19"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., and Montironi, R. (2020). Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells, 9.","DOI":"10.3390\/cells9122653"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.20517\/cdr.2022.83","article-title":"New insights for drug resistance in metastatic castration-resistant prostate cancer","volume":"5","author":"Kushwaha","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_10","first-page":"1677","article-title":"Management of advanced\/metastatic prostate cancer: 2000 update","volume":"14","author":"Hussain","year":"2000","journal-title":"Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urolonc.2009.03.016","article-title":"Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease","volume":"27","author":"Mostaghel","year":"2009","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","article-title":"Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer","volume":"10","author":"Zedan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_14","first-page":"339","article-title":"Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res. Rep. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1159\/000509434","article-title":"Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy","volume":"98","author":"Buonerba","year":"2020","journal-title":"Oncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urolonc.2009.11.003","article-title":"Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer","volume":"29","author":"Payne","year":"2011","journal-title":"Urol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101712"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1515\/cclm-2015-1073","article-title":"miRNAs as novel biomarkers in the management of prostate cancer","volume":"55","author":"Filella","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fonc.2019.00900","article-title":"Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction","volume":"9","author":"Bidarra","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ijc.25376","article-title":"Circulating miRNAs are correlated with tumor progression in prostate cancer","volume":"128","author":"Brase","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13346-013-0169-4","article-title":"Profiling of circulating microRNAs for prostate cancer biomarker discovery","volume":"4","author":"Haldrup","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","article-title":"PSA and beyond: Alternative prostate cancer biomarkers","volume":"39","author":"Saini","year":"2016","journal-title":"Cell. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: A step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102971","DOI":"10.1016\/j.dnarep.2020.102971","article-title":"Towards DNA-damage induced autophagy: A Boolean model of p53-induced cell fate mechanisms","volume":"96","author":"Gupta","year":"2020","journal-title":"DNA Repair"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112703","DOI":"10.1016\/j.biopha.2022.112703","article-title":"Deciphering the roles of miR-16-5p in malignant solid tumors","volume":"148","author":"Yang","year":"2022","journal-title":"Biomed. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/nan.12532","article-title":"MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy","volume":"45","author":"Krell","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_35","first-page":"137","article-title":"Role of miR-16-5p in the proliferation and metastasis of hepatocellular carcinoma","volume":"23","author":"Cheng","year":"2019","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/pin.12867","article-title":"miR-16-5p modulates the radiosensitivity of cervical cancer cells via regulating coactivator-associated arginine methyltransferase 1","volume":"70","author":"Zhang","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/21655979.2021.1924554","article-title":"Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)\/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p","volume":"12","author":"Wang","year":"2021","journal-title":"Bioengineered"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3892\/mmr.2021.12215","article-title":"MicroRNA-16-5p\/BIMP1\/NF-\u03baB axis regulates autophagy to exert a tumor-suppressive effect on bladder cancer","volume":"24","author":"He","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3892\/or.2020.7682","article-title":"MicroRNA-16-5p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells","volume":"44","author":"Wang","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00018-020-03634-4","article-title":"Interplay between HMGA and TP53 in cell cycle control along tumor progression","volume":"78","author":"Palumbo","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40001-022-00730-y","article-title":"CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer","volume":"27","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"563.e1","DOI":"10.1016\/j.clgc.2021.07.014","article-title":"Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article","volume":"19","author":"Cham","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/mol.114.097477","article-title":"Dual targeting of the androgen receptor and hypoxia-inducible factor 1\u03b1 pathways synergistically inhibits castration-resistant prostate cancer cells","volume":"87","author":"Fernandez","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jss.2018.11.030","article-title":"miR-145-5p suppresses breast cancer progression by inhibiting SOX2","volume":"236","author":"Tang","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1002\/jcp.27280","article-title":"Circ_0058063 regulates CDK6 to promote bladder cancer progression by sponging miR-145-5p","volume":"234","author":"Sun","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_46","first-page":"3026","article-title":"Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer","volume":"20","author":"Zhang","year":"2016","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.prnil.2014.09.001","article-title":"Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis","volume":"3","author":"Zhang","year":"2015","journal-title":"Prostate Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/bjc.2013.250","article-title":"The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients","volume":"108","author":"Avgeris","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_49","first-page":"1093","article-title":"Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1","volume":"38","author":"Fuse","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41391-021-00353-0","article-title":"CASC11 promotes aggressiveness of prostate cancer cells through miR-145\/IGF1R axis","volume":"24","author":"Capik","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1538-7445.AM2014-4356","article-title":"Tumor suppressive miRNA-145 inhibits IGF-1 and cell viability in prostate cancer cells","volume":"74","author":"Gaur","year":"2014","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biopha.2018.10.037","article-title":"Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis","volume":"109","author":"Zeinali","year":"2019","journal-title":"Biomed. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41420-022-01005-5","article-title":"Regulatory mechanism of miR-20a-5p expression in Cancer","volume":"8","author":"Huang","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M608939200","article-title":"An E2F\/miR-20a autoregulatory feedback loop","volume":"282","author":"Sylvestre","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cam4.1353","article-title":"LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p\/HMGA2 axis in breast cancer","volume":"7","author":"Zhao","year":"2018","journal-title":"Cancer Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2020.10.044","article-title":"Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3","volume":"498","author":"Qin","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3892\/ol.2021.12688","article-title":"miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1","volume":"21","author":"He","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ijc.29544","article-title":"Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma","volume":"137","author":"Wen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Daniel, R., Wu, Q., Williams, V., Clark, G., Guruli, G., and Zehner, Z. (2017). A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061281"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neo.2019.05.007","article-title":"The SOX4\/miR-17-92\/RB1 Axis Promotes Prostate Cancer Progression","volume":"21","author":"Liu","year":"2019","journal-title":"Neoplasia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13046-020-01718-4","article-title":"Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K\/AKT signaling pathway","volume":"39","author":"Li","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_62","first-page":"153245","article-title":"Licochalcone A reverses NNK-induced ectopic miRNA expression to elicit in vitro and in vivo chemopreventive effects","volume":"76","author":"Li","year":"2020","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2020.00107","article-title":"miR-20a-5p\/TGFBR2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis","volume":"10","author":"Fu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","article-title":"Androgen receptor and growth factor signaling cross-talk in prostate cancer cells","volume":"15","author":"Zhu","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pros.20698","article-title":"TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells","volume":"68","author":"Zhu","year":"2008","journal-title":"Prostate"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"19983","DOI":"10.1073\/pnas.0706641104","article-title":"An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells","volume":"104","author":"Shi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pros.21270","article-title":"miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes","volume":"71","author":"Shi","year":"2011","journal-title":"Prostate"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/onc.2012.55","article-title":"MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma","volume":"32","author":"Boll","year":"2013","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/hmg\/ddx138","article-title":"Clinical significance of miRNA host gene promoter methylation in prostate cancer","volume":"26","author":"Daniunaite","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_70","first-page":"4192","article-title":"Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor","volume":"76","author":"Sato","year":"2016","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.18632\/aging.101656","article-title":"miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer","volume":"10","author":"Chen","year":"2018","journal-title":"Aging"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sugita, B.M., Rodriguez, Y., Fonseca, A.S., Nunes Souza, E., Kallakury, B., Cavalli, I.J., Ribeiro, E., Aneja, R., and Cavalli, L.R. (2022). MiR-150-5p Overexpression in Triple-Negative Breast Cancer Contributes to the In Vitro Aggressiveness of This Breast Cancer Subtype. Cancers, 14.","DOI":"10.3390\/cancers14092156"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/0008-5472.CAN-10-2421","article-title":"Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells","volume":"71","author":"Ostling","year":"2011","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.4161\/cbt.7.8.6284","article-title":"MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer","volume":"7","author":"Rokhlin","year":"2008","journal-title":"Cancer Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2217\/pgs-2020-0008","article-title":"YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients","volume":"21","author":"Afonso","year":"2020","journal-title":"Pharmacogenomics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/caac.21391","article-title":"Prostate cancer\u2014Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2008.02.030","article-title":"Predicting survival in patients with advanced disease","volume":"44","author":"Glare","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Whittington","year":"1998","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"W409","DOI":"10.1093\/nar\/gkab297","article-title":"miRTargetLink 2.0-interactive miRNA target gene and target pathway networks","volume":"49","author":"Kern","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1002\/jcp.27989","article-title":"microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1\/E1-pRb-E2F1 pathway in prostate cancer cells","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/09553001003734568","article-title":"Transcriptional modulation of micro-RNA in human cells differing in radiation sensitivity","volume":"86","author":"Chaudhry","year":"2010","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e1109744","DOI":"10.1080\/23723556.2015.1109744","article-title":"miR-15\/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients","volume":"3","author":"Bonci","year":"2016","journal-title":"Mol. Cell. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Stoen, M.J., Andersen, S., Rakaee, M., Pedersen, M.I., Ingebriktsen, L.M., Donnem, T., Lombardi, A.P.G., Kilvaer, T.K., Busund, L.R., and Richardsen, E. (2021). Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study. Cancers, 13.","DOI":"10.3390\/cancers13164096"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/bjc.2014.181","article-title":"Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer","volume":"110","author":"Lin","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Deng, G., and Dahiya, R. (2012). MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029722"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/pros.21185","article-title":"MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms","volume":"70","author":"Kojima","year":"2010","journal-title":"Prostate"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s11033-021-06384-z","article-title":"Differentially expressed miR-20, miR-21, miR-100, miR-125a and miR-146a as a potential biomarker for prostate cancer","volume":"48","author":"Damodaran","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12094-019-02217-5","article-title":"MiR-130b\/TNF-alpha\/NF-kappaB\/VEGFA loop inhibits prostate cancer angiogenesis","volume":"22","author":"Mu","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-018-0102-0","article-title":"An integrated view of the role of miR-130b\/301b miRNA cluster in prostate cancer","volume":"7","author":"Fort","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2016.10.028","article-title":"Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1","volume":"385","author":"Martins","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/carcin\/bgv063","article-title":"miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis","volume":"36","author":"Larne","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"602493","DOI":"10.3389\/fcell.2020.602493","article-title":"The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing","volume":"8","author":"Guo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1038\/s41598-019-43231-5","article-title":"miR-150-5p represses TP53 tumor suppressor gene to promote proliferation of colon adenocarcinoma","volume":"9","author":"Liu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.juro.2017.02.823","article-title":"Mp28-10 panel of 6 micrornas for minimally invasive diagnosis of prostate cancer","volume":"197","author":"Alekseev","year":"2017","journal-title":"J. Urol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Costa, A.C., Santos, J.M.O., Medeiros-Fonseca, B., Oliveira, P.A., Bastos, M., Brito, H.O., Gil da Costa, R.M., and Medeiros, R. (2022). Characterizing the Inflammatory Microenvironment in K14-HPV16 Transgenic Mice: Mast Cell Infiltration and MicroRNA Expression. Cancers, 14.","DOI":"10.3390\/cancers14092216"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","article-title":"Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper\u2014Excel-based tool using pair-wise correlations","volume":"26","author":"Pfaffl","year":"2004","journal-title":"Biotechnol. Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2014.09.013","article-title":"MicroRNA and cancer\u2014A brief overview","volume":"57","author":"Acunzo","year":"2015","journal-title":"Adv. Biol. Regul."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/9101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:09Z","timestamp":1760125209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/9101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":99,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24109101"],"URL":"https:\/\/doi.org\/10.3390\/ijms24109101","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,5,22]]}}}